Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Neurogenet ; 25(4): 152-66, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22091727

RESUMEN

There is growing evidence suggesting that antagonists of group II metabotropic glutamate receptors (mGluR2/3) exhibit antidepressant-like properties in several preclinical models of depression. However, all those studies have been performed using competitive group II non-selective orthosteric antagonists. In this study we extensively characterized a group II selective negative allosteric modulator (4-[3-(2,6-Dimethylpyridin-4-yl)phenyl]-7-methyl-8-trifluoromethyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one, namely RO4491533, Woltering et al., 2010) in several in vitro biochemical assays and in vivo models of depression. In vitro, RO4491533 completely blocked the glutamate-induced Ca(2+) mobilization and the glutamate-induced accumulation in [(35)S]GTP(γS) binding in cells expressing recombinant human or rat mGluR2 and in native tissues. Results from Schild plot experiments and reversibility test at the target on both cellular and membrane-based assays confirmed the negative allosteric modulator properties of the compound. RO4491533 was equipotent on mGluR2 and mGluR3 receptors but not active on any other mGluRs. RO4491533 has acceptable PK properties in mice and rats, is bioavailable following oral gavage (F = 30%) and brain-penetrant (CSF conc/total plasma conc ratio = 0.8%). RO4491533 appeared to engage the central mGluR2 and mGluR3 receptors since the compound reversed the hypolocomotor effect of an mGluR2/3 orthosteric agonist LY379268 in a target-specific manner, as did the group II orthosteric mGluR2/3 antagonist LY341495. RO4491533 and LY341495 dose-dependently reduced immobility time of C57Bl6/J mice in the forced swim test. Also, RO4491533 and LY341495 were active in the tail suspension test in a line of Helpless (H) mice, a putative genetic model of depression. These data suggest that mGluR2/3 receptors are viable targets for development of novel pharmacotherapies for depression.


Asunto(s)
Antidepresivos/farmacología , Benzodiazepinas/farmacología , Benzodiazepinonas/farmacología , Trastorno Depresivo/tratamiento farmacológico , Receptores de Glutamato Metabotrópico/antagonistas & inhibidores , Regulación Alostérica/efectos de los fármacos , Regulación Alostérica/genética , Animales , Antidepresivos/uso terapéutico , Benzodiazepinas/uso terapéutico , Benzodiazepinonas/uso terapéutico , Trastorno Depresivo/genética , Trastorno Depresivo/metabolismo , Modelos Animales de Enfermedad , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratas , Ratas Sprague-Dawley , Receptores de Glutamato Metabotrópico/metabolismo
2.
Ann Pharm Fr ; 62(5): 332-42, 2004 Sep.
Artículo en Francés | MEDLINE | ID: mdl-15314581

RESUMEN

Depression is a multifactorial illness and genetic factors play a role in its etiology. The understanding of its pathophysiology relies on the availability of experimental models potentially mimicking the disease. Here is presented a model built up by selective breeding of mice with strikingly different responses in the tail suspension test, a stress paradigm aimed at screening potential antidepressants. Indeed, "helpless" mice are essentially immobile in the tail suspension test, as well as the Porsolt forced-swim test, and they show reduced consumption of a palatable 2% sucrose solution. In addition, helpless mice exhibit sleep-wakefulness alterations resembling those classically observed in depressed patients, notably a lighter and more fragmented sleep, with an increase pressure of rapid eye movement sleep. Compared with "nonhelpless" mice, they display higher basal serum corticosterone levels and lower serotonin metabolism index in the hippocampus. Remarkably, serotonin1A autoreceptor stimulation induced greatest hypothermia and inhibition of serotoninergic neuronal firing in the nucleus raphe dorsalis in helpless than in nonhelpless mice. Thus, helpless mice exhibit a decrease in serotoninergic tone, which evokes that associated with endogenous depression in humans. Finally, both the behavioral impairments and the serotoninergic dysfunction can be improved by chronic treatment with the antidepressant fluoxetine. The helpless line of mice may provide an opportunity to approach genes influencing susceptibility to depression and to investigate neurophysiological and neurochemical substrates underlying antidepressant effects.


Asunto(s)
Trastorno Depresivo/psicología , Animales , Química Encefálica/fisiología , Trastorno Depresivo/etiología , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Receptor de Serotonina 5-HT1A/fisiología
3.
J Neuroendocrinol ; 15(12): 1171-7, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14636179

RESUMEN

A2A receptor knockout (A2AR-/-) mice are more anxious and aggressive, and exhibit reduced exploratory activity than their wild-type littermates (A2AR+/+). Because alpha-melanocyte-stimulating hormone (alpha-MSH) influences anxiety, aggressiveness and motor activity, we investigated the effect of A2AR gene disruption on alpha-MSH content in discrete brain regions and pro-opiomelanocortin (POMC) expression in the hypothalamus and pituitary. No modification in alpha-MSH content was observed in the hypothalamus and medulla oblongata where POMC-expressing perikarya are located. In the arcuate nucleus of the hypothalamus, POMC mRNA levels were not affected by A2AR disruption. Conversely, in A2AR-/- mice, a significant increase in alpha-MSH content was observed in the amygdala and cerebral cortex, two regions that are innervated by POMC terminals. In the pars intermedia of the pituitary, A2AR disruption provoked a significant reduction of POMC mRNA expression associated with a decrease in alpha-MSH content. By contrast, in the anterior lobe of the pituitary, a substantial increase in POMC mRNA and adrenocorticotropin hormone concentrations was observed, and plasma corticosterone concentration was significantly higher in A2AR-/- mice, revealing hyperactivity of their pituitary-adrenocortical axis. Together, these results suggest that adenosine, acting through A2A receptors, may modulate the release of alpha-MSH in the cerebral cortex and amygdala. The data also indicate that A2A receptors are involved in the control of POMC gene expression and biosynthesis of POMC-derived peptides in pituitary melanotrophs and corticotrophs.


Asunto(s)
Adenohipófisis/fisiología , Proopiomelanocortina/metabolismo , Receptor de Adenosina A2A/genética , alfa-MSH/metabolismo , Animales , Expresión Génica , Hipotálamo/citología , Hipotálamo/fisiología , Masculino , Bulbo Raquídeo/citología , Bulbo Raquídeo/fisiología , Ratones , Ratones Endogámicos , Ratones Noqueados , Adenohipófisis/citología , ARN Mensajero/análisis
4.
Neuropharmacology ; 45(7): 977-85, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14573390

RESUMEN

The role of the adenosine A(2A) receptor in the hypnotic effects of ethanol was assessed in mice. The duration of the loss of righting reflex following acute ethanol administration was shorter for A(2A) receptor-deficient mice (A(2A)R KO) than for wild-type mice (A(2A)R WT), whereas the fall in body temperature was not different between the two phenotypes. In contrast, the duration of the loss of righting reflex was increased in A(2A)R KO mice versus controls after administration of pentobarbital. Dipyridamole, an inhibitor of adenosine uptake, increased the sleep time observed following administration of ethanol in CD1 mice and in A(2A)R WT but not in A(2A)R KO mice. SCH 58261, a selective A(2A) receptor antagonist, unlike DPCPX, a selective A(1) receptor antagonist, shortened the duration of the loss of righting reflex induced by ethanol, thus mimicking the lack of receptor in deficient mice. Finally, the non-selective adenosine receptor antagonist caffeine (25 mg/kg) reduced ethanol-induced hypnotic effects. These results indicate that the activation of A(2A) receptors that follows an increase in extracellular adenosine levels caused by the administration of high doses of ethanol plays a role in its hypnotic effects. Thus, A(2A) receptor antagonists may be useful therapeutic agents for alleviating ethylic coma.


Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Cafeína/farmacología , Depresores del Sistema Nervioso Central/antagonistas & inhibidores , Estimulantes del Sistema Nervioso Central/farmacología , Etanol/antagonistas & inhibidores , Antagonistas del Receptor de Adenosina A1 , Animales , Temperatura Corporal/efectos de los fármacos , Depresores del Sistema Nervioso Central/envenenamiento , Dipiridamol/farmacología , Sobredosis de Droga/tratamiento farmacológico , Etanol/envenenamiento , Hipnóticos y Sedantes/farmacología , Masculino , Ratones , Ratones Noqueados , Fármacos Neuroprotectores/farmacología , Pentobarbital/farmacología , Equilibrio Postural/efectos de los fármacos , Pirimidinas/farmacología , Receptor de Adenosina A2A/genética , Triazoles/farmacología , Vasodilatadores/farmacología , Xantinas/farmacología
5.
Chir Main ; 21(1): 51-5, 2002 Jan.
Artículo en Francés | MEDLINE | ID: mdl-11885390

RESUMEN

A case of simultaneous proximal radio ulnar joint divergent dislocation combined with a bone avulsion of the coronoid apophysis of the same elbow in a 16 years-old girl is presented. After a closed reduction and two weeks of plaster immobilization, normal function of the elbow was recovered within three months. There are only ten cases reported of such a divergent elbow dislocation in modern literature.


Asunto(s)
Lesiones de Codo , Luxaciones Articulares/patología , Procedimientos Ortopédicos/métodos , Adolescente , Codo/patología , Codo/cirugía , Femenino , Humanos , Inmovilización , Luxaciones Articulares/cirugía , Radio (Anatomía)/patología , Cúbito/patología
6.
Eur J Neurosci ; 14(9): 1567-70, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11722618

RESUMEN

The selective A2A receptor antagonist [3H]SCH 58261 was injected intravenously in mice and the radioactivity accumulating in various brain regions was determined by tissue sampling. Radioactivity levels in regions of interest such as the striatum were highest 15 min after injection and quickly declined thereafter (30 min and 1 h postinjection) in a time-dependent manner. The amount of labelling was ranked as follows: striatum (4.6 +/- 0.3 fmol/mg protein) >> cortex > hippocampus > pons = hypothalamus > cerebellum (0.5 +/- 0.05 fmol/mg protein). Specific labelling of the A2A receptor occurred in striatum and cortex because significantly less radioactivity accumulated in these areas from adenosine A2A receptor knockout mice as compared to wild-type littermates. In control outbred CD1 mice, a striatum-to-cerebellum ratio of 7.6 +/- 0.6 was found. At 30 min postinjection, the nonselective adenosine receptor antagonist caffeine reduced the radioactivity due to [3H]SCH 58261 in the striatum by 32% at 1 mg/kg i.p. and by 66% at the stimulant dose of 6.25 mg/kg i.p. Radioactivity in the striatum was lowered, respectively, by 66 and 86% 30 min after injection of 3 or 10 mg/kg i.p. doses of unlabelled SCH 58261. The present results indicate that [3H]SCH 58261 directly labels striatal A2A receptors in vivo. Thus [3H]SCH 58261 is an excellent tool for studying brain distribution and A2A receptor occupancy of various compounds ranging from xanthines, such as caffeine, to other A2A antagonists.


Asunto(s)
Adenosina/metabolismo , Encéfalo/efectos de los fármacos , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/metabolismo , Antagonistas de Receptores Purinérgicos P1 , Pirimidinas/metabolismo , Triazoles/metabolismo , Animales , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Unión Competitiva/efectos de los fármacos , Unión Competitiva/fisiología , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/fisiología , Encéfalo/citología , Encéfalo/metabolismo , Cafeína/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Masculino , Ratones , Ratones Noqueados , Neuronas/metabolismo , Inhibidores de Fosfodiesterasa/farmacología , Ensayo de Unión Radioligante , Receptor de Adenosina A2A , Receptores Purinérgicos P1/deficiencia , Receptores Purinérgicos P1/genética , Tritio/metabolismo
7.
Br J Pharmacol ; 134(1): 68-77, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11522598

RESUMEN

1. Adenosine, an ubiquitous neuromodulator, and its analogues have been shown to produce 'depressant' effects in animal models believed to be relevant to depressive disorders, while adenosine receptor antagonists have been found to reverse adenosine-mediated 'depressant' effect. 2. We have designed studies to assess whether adenosine A2A receptor antagonists, or genetic inactivation of the receptor would be effective in established screening procedures, such as tail suspension and forced swim tests, which are predictive of clinical antidepressant activity. 3. Adenosine A2A receptor knockout mice were found to be less sensitive to 'depressant' challenges than their wildtype littermates. Consistently, the adenosine A2A receptor blockers SCH 58261 (1 - 10 mg kg(-1), i.p.) and KW 6002 (0.1 - 10 mg kg(-1), p.o.) reduced the total immobility time in the tail suspension test. 4. The efficacy of adenosine A2A receptor antagonists in reducing immobility time in the tail suspension test was confirmed and extended in two groups of mice. Specifically, SCH 58261 (1 - 10 mg kg(-1)) and ZM 241385 (15 - 60 mg kg(-1)) were effective in mice previously screened for having high immobility time, while SCH 58261 at 10 mg kg(-1) reduced immobility of mice that were selectively bred for their spontaneous 'helplessness' in this assay. 5. Additional experiments were carried out using the forced swim test. SCH 58261 at 10 mg kg(-1) reduced the immobility time by 61%, while KW 6002 decreased the total immobility time at the doses of 1 and 10 mg kg(-1) by 75 and 79%, respectively. 6. Administration of the dopamine D2 receptor antagonist haloperidol (50 - 200 microg kg(-1) i.p.) prevented the antidepressant-like effects elicited by SCH 58261 (10 mg kg(-1) i.p.) in forced swim test whereas it left unaltered its stimulant motor effects. 7. In conclusion, these data support the hypothesis that A2A receptor antagonists prolong escape-directed behaviour in two screening tests for antidepressants. Altogether the results support the hypothesis that blockade of the adenosine A2A receptor might be an interesting target for the development of effective antidepressant agents.


Asunto(s)
Antidepresivos/farmacología , Antagonistas de Receptores Purinérgicos P1 , Animales , Conducta Animal/efectos de los fármacos , Blefaroptosis/inducido químicamente , Blefaroptosis/prevención & control , Modelos Animales de Enfermedad , Antagonistas de Dopamina/farmacología , Antagonistas de los Receptores de Dopamina D2 , Relación Dosis-Respuesta a Droga , Femenino , Haloperidol/farmacología , Inmovilización , Masculino , Ratones , Ratones Noqueados , Actividad Motora/efectos de los fármacos , Purinas/farmacología , Pirimidinas/farmacología , Receptor de Adenosina A2A , Receptores de Dopamina D2/fisiología , Receptores Purinérgicos P1/genética , Reserpina/administración & dosificación , Natación , Factores de Tiempo , Triazoles/farmacología
8.
Rev Chir Orthop Reparatrice Appar Mot ; 87(4): 397-401, 2001 Jun.
Artículo en Francés | MEDLINE | ID: mdl-11431637

RESUMEN

We report four cases of echinococcosis of the pelvic bone in 3 women and a man aged 30 to 55 years. Disease spread was wide, involving the entire hemipelvis in one case and the sacrum in another making surgical excision difficult. In two cases, computed tomography was highly contributive to diagnosis and assessment of local extension. We used surgical excision and hydrogen peroxide sterilization for the first two case. For the two last cases, we used albendazole in four 4-week cures at a 2-week interval before and after surgery. The clinical course was favorable to these two cases at 3 and 4 years. The albendazole-surgery combination appears to be the best therapeutic option.


Asunto(s)
Enfermedades Óseas Infecciosas/diagnóstico por imagen , Enfermedades Óseas Infecciosas/terapia , Equinococosis/diagnóstico por imagen , Equinococosis/terapia , Huesos Pélvicos , Adulto , Albendazol/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Anticestodos/uso terapéutico , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Peróxido de Hidrógeno/uso terapéutico , Masculino , Persona de Mediana Edad , Osteotomía , Selección de Paciente , Atención Perioperativa , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
9.
Neuroreport ; 12(5): 983-6, 2001 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-11303773

RESUMEN

Catalepsy assessed using the bar test was measured in both adenosine A2A receptor knockout (A2AR KO) and wild-type (A2AR WT) mice submitted to acute administration of the dopamine D2 receptor antagonist haloperidol (0.5, 2, 4, 6 mg/kg i.p.), the dopamine D1 antagonist SCH 23390 (0.3-3 mg/kg, s.c.), the vesicular monoamine transporter blocker reserpine (3-5 mg/kg, s.c.) or the acetylcholine muscarinic receptor agonist pilocarpine (25-50 mg/kg, i.p.). Except for reserpine, catalepsy scores were significantly lower in A2AR KO mice than in A2AR WT mice following low doses of these cataleptogenic agents. These results suggest that adenosine A2A receptors influence not only dopamine D2 and D1 receptor-mediated neurotransmission but also acetylcholine muscarinic receptor-mediated neurotransmission.


Asunto(s)
Catalepsia/inducido químicamente , Receptores Purinérgicos P1/fisiología , Animales , Benzazepinas , Catalepsia/genética , Antagonistas de Dopamina , Haloperidol , Masculino , Ratones , Ratones Noqueados , Agonistas Muscarínicos , Pilocarpina , Receptor de Adenosina A2A , Receptores Purinérgicos P1/genética , Reserpina , Simpaticolíticos
10.
Neuropharmacology ; 40(3): 424-32, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11166335

RESUMEN

Considering the existing interactions between ethanol and adenosine, the influence of the genetic impairment of the adenosine A(2A) receptor has been examined upon the seizures occurring at the cessation of chronic ethanol intake or 'ethanol withdrawal' in male mice. Acute clearance of ethanol did not differ between adenosine A(2A) receptor knockout and wild-type mice. Mice were exposed for 10 days to a diet consisting of a milky chocolate drink that contained increasing concentrations (1.8, 3.6 and 6.3% v/v) of ethanol. Adenosine A(2A) receptor knockout mice ingested similar amounts of the fluid, either containing alcohol or not, as did the controls. The severity of handling-induced convulsions during withdrawal was significantly reduced in the adenosine A(2A) receptor knockout mice as compared with their wild-type controls. The selective adenosine A(2A) receptor antagonist ZM 241385 (20 mg/kg) also significantly attenuated the intensity of withdrawal-induced seizures occurring in wild-type male mice when intraperitoneally administered twice daily during the last 5 days of the forced alcohol intake. These results suggest that selective adenosine A(2A) receptor antagonists may be useful in the treatment of alcohol withdrawal.


Asunto(s)
Convulsiones por Abstinencia de Alcohol/genética , Antagonistas de Receptores Purinérgicos P1 , Receptores Purinérgicos P1/deficiencia , Administración Oral , Convulsiones por Abstinencia de Alcohol/prevención & control , Animales , Bebidas , Cacao , Modelos Animales de Enfermedad , Esquema de Medicación , Ingestión de Alimentos/efectos de los fármacos , Etanol/administración & dosificación , Etanol/sangre , Femenino , Aromatizantes , Inyecciones Intraperitoneales , Masculino , Ratones , Ratones Noqueados , Receptor de Adenosina A2A , Receptores Purinérgicos P1/genética , Triazinas/administración & dosificación , Triazoles/administración & dosificación
11.
Eur J Pharmacol ; 401(1): 63-77, 2000 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-10915839

RESUMEN

The acute motor effects elicited by drugs acting upon adenosine A(2A) receptors, namely the highly selective agonist CGS 21680 or the antagonists SCH 58261 and ZM 241385, were investigated in mice. CGS 21680 dose-dependently (0.1-2.5 mg/kg i.p.) decreased horizontal and vertical motor activities. The depressant effect of CGS 21680 (0. 5 mg/kg i.p.) was maintained in mice pretreated by the adenosine receptor antagonist 8-(p-sulfophenyl)-theophylline (10-30 mg/kg i.p. ), which poorly penetrates the blood-brain barrier, but was completely lost in adenosine A(2A) receptor knockout mice. Thus, the adenosine A(2A) receptor is critically involved in motor activity. SCH 58261 (1-10 mg/kg i.p.) increased locomotion and rearing with a quick onset, but for a shorter period in mice habituated to the environment than in mice unfamiliar to it. ZM 241385 (7.5-60 mg/kg i. p.) stimulated horizontal and vertical activities with a slow onset at the two highest tested doses, similarly in naive and in habituated mice. The increase in locomotion elicited by ZM 241385 (15-30 mg/kg i.p. and 10-20 nM i.c.v.) was retained in mice treated by CGS 21680 (0.5 mg/kg i.p.) but that elicited by SCH 58261 (1-3-10 mg/kg i.p. and 10-20 nM i.c.v.) partially subsided. In conclusion, both 'striatal-like'/'SCH 58261-sensitive' adenosine A(2A) receptors and 'ZM 241385-sensitive'/'atypical' CGS 21680 binding sites may mediate CGS 21680-induced motor effects. Moreover, our results suggest that 'atypical' CGS 21680 binding sites could be adenosine A(2A) receptors with a peculiar pharmacological profile.


Asunto(s)
Adenosina/análogos & derivados , Adenosina/farmacología , Actividad Motora/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Fenetilaminas/farmacología , Pirimidinas/farmacología , Triazinas/farmacología , Triazoles/farmacología , Animales , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Conducta Exploratoria/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Noqueados , Receptor de Adenosina A2A , Receptores Purinérgicos P1/efectos de los fármacos , Receptores Purinérgicos P1/genética , Receptores Purinérgicos P1/fisiología , Factores de Tiempo
12.
Br J Pharmacol ; 129(7): 1465-73, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10742303

RESUMEN

1. The locomotor stimulatory effects induced by caffeine (1,3, 7-trimethylxanthine) in rodents have been attributed to antagonism of adenosine A(1) and A(2A) receptors. Little is known about its locomotor depressant effects seen when acutely administered at high doses. The roles of adenosine A(1) and A(2A) receptors in these activities were investigated using a Digiscan actimeter in experiments carried out in mice. Besides caffeine, the A(2A) antagonist SCH 58261 (5-amino-7-(beta-phenylethyl)-2-(8-furyl)pyrazolo[4,3-e]-1,2, 4-triazolo[1,5-c]pyrimidine), the A(1) antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine), the A(1) agonist CPA (N(6)-cyclopentyladenosine) and A(2A) receptor knockout mice were used. 2. Caffeine had a biphasic effect on locomotion of wild-type mice not habituated to the open field, stimulating locomotion at 6.25 - 25 mg kg(-1) i.p. doses, while depressing it at 100 mg kg(-1). In sharp contrast, caffeine dose-dependently decreased locomotion in A(2A) receptor knockout mice over the whole range of tested doses. 3. The depressant effects induced by high doses of caffeine were lost in control CD1 mice habituated to the open field. 4. The A(1) agonist CPA depressed locomotion at 0.3 - 1 mg kg(-1) i.p. doses. 5. The A(1) antagonist DPCPX decreased locomotion of A(2A) receptor knockouts and CD1 mice at 5 mg kg(-1) i.p. and 25 mg kg(-1) i.p. respectively. 6. DPCPX (0.2 - 1 mg kg(-1) i.p.) left unaltered or even reduced the stimulant effect of SCH 58261 (1 - 3 mg kg(-1) i.p.) on CD1 mice. 7. These results suggest therefore that the stimulant effect of low doses of caffeine is mediated by A(2A) receptor blockade while the depressant effect seen at higher doses under some conditions is explained by A(1) receptor blockade.


Asunto(s)
Conducta Animal/efectos de los fármacos , Cafeína/farmacología , Estimulantes del Sistema Nervioso Central/farmacología , Actividad Motora/efectos de los fármacos , Antagonistas de Receptores Purinérgicos P1 , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Habituación Psicofisiológica , Masculino , Ratones , Ratones Noqueados , Pirimidinas/farmacología , Receptor de Adenosina A2A , Receptores Purinérgicos P1/genética , Receptores Purinérgicos P1/fisiología , Triazoles/farmacología , Xantinas/farmacología
13.
Psychopharmacology (Berl) ; 148(2): 153-63, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10663430

RESUMEN

RATIONALE: The elevated plus-maze and the light/dark box are two established anxiety tests in rodents, which are useful to screen putative anxiogenic effects of drugs. OBJECTIVE: Caffeine is well known to promote anxious behaviour in humans and animal models, but the precise site of action of the drug is still a matter of debate. The present study investigated whether the anxiogenic effects of caffeine observed in mice depend on the blockade of A(2A) receptor. First, the effects induced by the non-selective drug caffeine were compared with those elicited by two selective A(2A) receptor antagonists over a wide range of doses in the same experimental conditions. The effects of A(2A) or A(1 )adenosine receptor agonists and of a selective A(1) adenosine receptor antagonist were also investigated. Second, wild-type and A(2A) receptor knockout mice offered another approach to delineate the role played by A(2A) receptor in caffeine's anxiogenic effects. METHODS: Mice were exposed to the elevated plus-maze or to the light/dark box for 5 min after acute or chronic administration of tested drugs. RESULTS: Caffeine acutely administered (50 or 100 mg/kg IP) induced anxiety-like effects in both procedures. Its chronic administration (50 mg/kg IP twice daily) for 1 week or consumption in the drinking water (0.3 g/l) for 8 days or 2 months were also anxiogenic in the plus-maze test. The A(2A) receptor antagonists ZM241385 (up to 60 mg/kg IP) and SCH58261 (up to 10 mg/kg IP) were devoid of acute effects in both tests. One week administration of ZM241385 (30 mg/kg IP) or SCH58261 (3 mg/kg IP) had no effects in the plus-maze test. An antagonist (DPCPX) and an agonist (CPA) at A(1) receptors had no acute effects on anxiety-related indices, whereas an A(2A) receptor agonist (CGS 21680) displayed non-specific motor effects in the plus-maze test. Acute administration of caffeine (50 mg/kg IP) induced no clear-cut anxiety-like effects in the plus-maze test in A(2A) receptor knockout mice that exhibited higher basal anxiety levels than wild-type mice. Chronic administration (50 mg/kg IP twice daily) for 1 week elicited less anxiety-like behaviour in A(2A) receptor knockout than in wild-type mice. CONCLUSIONS: Adaptative mechanisms following mutation in A(2A) receptors or their long-term blockade after chronic ingestion of caffeine may be responsible for increase proneness to anxiety. However, the short-term anxiety-like effect of caffeine in mice might not be related solely to the blockade of adenosine A(2A) receptors, since it is not shared by A(2A) selective antagonists.


Asunto(s)
Ansiedad/inducido químicamente , Cafeína/administración & dosificación , Antagonistas de Receptores Purinérgicos P1 , Adenosina/administración & dosificación , Adenosina/análogos & derivados , Administración Oral , Animales , Ansiedad/tratamiento farmacológico , Conducta Animal/efectos de los fármacos , Oscuridad , Esquema de Medicación , Inyecciones Intraperitoneales , Luz , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Noqueados , Fármacos Neuroprotectores/administración & dosificación , Fenetilaminas/administración & dosificación , Agonistas del Receptor Purinérgico P1 , Pirimidinas/administración & dosificación , Tiempo de Reacción/efectos de los fármacos , Receptor de Adenosina A2A , Triazinas/administración & dosificación , Triazoles/administración & dosificación , Xantinas/administración & dosificación
14.
Nature ; 388(6643): 674-8, 1997 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-9262401

RESUMEN

Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degradation of released ATP. It is a potent biological mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculature. Most of these effects help to protect cells and tissues during stress conditions such as ischaemia. Adenosine mediates its effects through four receptor subtypes: the A1, A2a, A2b and A3 receptors. The A2a receptor (A2aR) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase. It is a major target of caffeine, the most widely used psychoactive drug. Here we investigate the role of the A2a receptor by disrupting the gene in mice. We found that A2aR-knockout (A2aR-/-) mice were viable and bred normally. Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behaviour, became a depressant of exploratory activity. Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders. The response of A2aR-/- mice to acute pain stimuli was slower. Blood pressure and heart rate were increased, as well as platelet aggregation. The specific A2a agonist CGS 21680 lost its biological activity in all systems tested.


Asunto(s)
Receptores Purinérgicos P1/fisiología , Adenosina/análogos & derivados , Adenosina/farmacología , Adenosina/fisiología , Agresión/fisiología , Animales , Presión Sanguínea/fisiología , Encéfalo/fisiología , Cafeína/farmacología , Clonación Molecular , Frecuencia Cardíaca/fisiología , Humanos , Hipertensión/etiología , Masculino , Ratones , Ratones Noqueados , Datos de Secuencia Molecular , Dolor , Fenetilaminas/farmacología , Agregación Plaquetaria/fisiología , Antagonistas de Receptores Purinérgicos P1 , Receptores Purinérgicos P1/deficiencia , Receptores Purinérgicos P1/genética , Mapeo Restrictivo , Homología de Secuencia de Aminoácido
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...